Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.
Adellina Numbing Cream Lidocaine 5 g/100mL Cream, 44 mL — NDC 60771-0011-1 (Billing 60771-0011-01)
by Guangzhou Haishi Biological Technology Co., Ltd. · 44 mL in 1 BOTTLE
This is a package of 44 mL of Adellina Numbing Cream Lidocaine 5 g/100mL Cream from Guangzhou Haishi Biological Technology Co., Ltd., marketed since Mar 2025 and currently FDA-listed. It is this product's only package size.
NDC 60771-0011-01
🏷️ FDA NDC (as labeled)
60771-0011-1
billing pads the package segment with a zero
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
⚠️
Other active recalls for Lidocaine (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · Apr 20, 2023 — Labeling: Typographical error on the upper left-hand side of the box and individual patch label that has the incorrect dosage form stating, each tablet contains instead of each adhesive patch contains. (Bryant Ranch Prepack, Inc.) · FDA recall D-0556-2023
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
FDA NDC (as labeled)
60771-0011-1
Product NDC
60771-0011
11-digit billing NDC
60771001101
RxCUI
1534792
UNII
98PI200987
Application #
M017
SPL Set ID
314a83fe-8bdb-766f-e063-6294a90a61c6
Established class (EPC)
Amide Local Anesthetic; Antiarrhythmic
Physiologic effect
Local Anesthesia
Chemical class
Amides
DEA schedule
Non-controlled
Marketing category
OTC MONOGRAPH DRUG
Marketing status
On market
FDA listing status
Listed (active directory)
Marketing start
2025-03-27
Route
TOPICAL
Dosage form
CREAM
Substance
LIDOCAINE
Quick answers
- RxCUI (RxNorm): 1534792
Why two NDCs?
The FDA registers this code as 60771-0011-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 60771-0011-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Antiarrhythmic class.
Pharmacologic class
Antiarrhythmic, Amide Local Anesthetic
Drug family (ATC)
Antiarrhythmics, class Ib, Local anesthetics, Anesthetics for topical use
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
📗 Our plain-language guide HelloPharmacist
- Lidocaine numbs the area where it is used. Clinicians inject it for procedures. Skin products are used for pain, itching, minor burns, insect bites, hemorrhoid discomfort, and in s...
- Clean and dry the skin first, then apply as your product’s directions say. Wash your hands afterward. Don’t exceed the number of uses on the label. Ask a doctor before using a prod...
- No. Heat can increase how much lidocaine your body absorbs. Don’t bandage tightly either. Also avoid using other topical pain products at the same time.
- Can I use a heating pad with a lidocaine patch?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Lidocaine — tap one for details:
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
💬 Questions about Lidocaine?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 2, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 60771-0011-01 You're viewing this Main listing | 44 mL in 1 BOTTLE | 2025-03-27 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Lidocaine 50 mg/g 58980-0823-30 | STRATUS | 1 tube | — | — | FDA listed | — |
| Adellina Tattoo Numbing Cream 5 g/100g 60771-0010-01 | Guangzhou | 50 g | — | — | Discontinued | — |
| Adellina Numbing Cream 5 g/100mLthis 60771-0011-01 | Guangzhou | 44 ml | — | — | FDA listed | — |
| Lipocaine 5 5 g/100g 63135-0811-04 | ESBA | 113 g | — | — | FDA listed | — |
| Microcaine Topical Analgesic 50 mg/g 67194-0022-01 | Unit | 15 g | — | — | FDA listed | — |
| Hempvana Maximum Strength Pain Relief Topical Anesthetic 5 g/100g 73287-0026-01 | Telebrands | 1 jar | — | — | FDA listed | — |
| Lidocaine 5 g/100mL 73581-0022-06 | YYBA | 170 ml | — | — | FDA listed | — |
| Lidocaine Numbing Cream 50 mg/mL 73581-0105-55 | Yyba | 156 ml | — | — | FDA listed | — |
| Lidocaine 5 g/100mL 73581-0114-01 | YYBA | 30 ml | — | — | FDA listed | — |
| Numbing Cream 5 g/100mL 82929-0011-01 | Sainite | 1 bottle | — | — | FDA listed | — |
| Healcome Lidocaine Numbing Cream 5 g/100g 83364-0024-01 | YITONGBADA | 1 bottle | — | — | FDA listed | — |
| Pressy Tattoo Numbing Cream 5 g/100g 83887-0008-01 | Changsha | 60 g | — | — | Discontinued | — |
| Tattoo Numbing Cream 5 g/100mL 83887-0009-01 | Changsha | 60 ml | — | — | Discontinued | — |
| Lidocaine 5% 5 g/100g 84007-0335-01 | Medhome | 30 g | — | — | FDA listed | — |
| Signature Lidocaine Pain Relief Cream 50 mg/g 84019-0043-01 | Shengnan | 30 g | — | — | FDA listed | — |
| ElixirLidoFast .05 g/g 84546-0010-01 | ELIXIR | 1 tube | — | — | FDA listed | — |
| VTROUY Tattoo Numbing Cream 5 g/100g 85150-0004-01 | Guangzhou | 50 g | — | — | FDA listed | — |
| Dr.pabu Numbing 5 g/100g 85248-0177-01 | Jiangxi | 50 g | — | — | FDA listed | — |
| Tattoo numbing 3 g/60g 85342-0002-01 | Guangzhou | 60 g | — | — | Discontinued | — |
| Arlun LIDOCAINE Cream 5 g/100g 87408-0021-01 | Guangzhou | 1 bottle | — | — | FDA listed | — |
| Numbskin Maximum Strength Pain Reliever 5 g/100mL 69903-0008-30 | Shinpharma | 60 ml | — | — | FDA listed | — |
| Hilook Blue Gel Anesthetic 5 g/100mL 83566-0143-01 | Guangdong | 30 ml | — | — | FDA listed | — |
| Dr. Numb 5 g/100mL 69903-0006-02 | Shinpharma | 60 ml | — | — | FDA listed | — |
| VBBV Anorectal(Hemorrhoidal) Creams 5 g/100mL 84867-0020-01 | Jiashen | 60 ml | — | — | FDA listed | — |
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Sep 3, 2026
- CMS NADAC weekly file
Availability & generic status
🏛️
2025
On the market since
Mar 2025
📍
2026
Currently FDA-listed
1 year listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available
FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
- FDA Orange Book · refreshed Sep 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII TR046Y3K1G
A liquid alcohol derived from petroleum or plant sources. It acts as a solvent and humectant in medicines, helping dissolve active ingredients and retain moisture in the formulation.
-
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
2 inactive ingredients listed in the exact product block matched to this NDC.
The official label also statesAQUA 71.3% PROPYLENE 5% CARBOMER 0.25% GLYCERIN 5% DISODIUM EDTA 0.05% HYDROXYACETOPHENONE 0.4% 1,2-HEXANEDIOL 5% MENTHA ARVENSIS LEAF EXTRACT 2% CHRYSANTHELLUM INDICUM EXTRACT 2% PORTULACA OLERACEA EXTRACT 2% PEG-40 HYDROGENATED CASTOR OIL 2%
Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.
Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed —
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 1, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
Manufacturer & labeler
LabelerGuangzhou Haishi Biological Technology Co., Ltd.
FDA applicationM017 (OTC MONOGRAPH DRUG)
Labeler code60771
First marketedMar 2025
Product typeHuman Otc Drug
Portfolio34 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
FDA label — Drug Facts FDA SPL
The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage
⏱️ Dosage and Administration
⚠️ Warnings
🧪 Active Ingredient
🧪 Inactive Ingredients
🎯 Purpose
📄 Do Not Use
📄 When Using This Product
📄 Stop Use and Ask a Doctor If
📄 Keep Out of Reach of Children
📄 Package Label / Principal Display Panel
🎯 Indications and Usage ▾
Uses For the physical or local anesthesia associated with tattoo
⏱️ Dosage and Administration ▾
Dosage Squeeze out an appropriate amount of product and spread evenly on skin.
⚠️ Warnings ▾
For external use only. Avoid contact with the eyes Keep away from heat or flame. Do not use in large quantities, particularly over raw surfaces or blistered areas.
🧪 Active Ingredient ▾
Active ingredients Lidocaine 5%
🧪 Inactive Ingredients ▾
Inactive ingredients AQUA 71.3% PROPYLENE 5% CARBOMER 0.25% GLYCERIN 5% DISODIUM EDTA 0.05% HYDROXYACETOPHENONE 0.4% 1,2-HEXANEDIOL 5% MENTHA ARVENSIS LEAF EXTRACT 2% CHRYSANTHELLUM INDICUM EXTRACT 2% PORTULACA OLERACEA EXTRACT 2% PEG-40 HYDROGENATED CASTOR OIL 2%
🎯 Purpose ▾
Purpose Local Anesthetic
📄 Do Not Use ▾
Do not use this product if Pregnant or breastfeeding, ask a health professional before use. In case of accidental overdose, get medical help or contact the Poison Control Center immediately. Seal is broken or missing.
📄 When Using This Product ▾
Do not exceed the recommended daily dosage unless directed by a doctor. certain persons can develop allergic reactions to ingredients in this product. do not put this product into the rectum by using finger.
📄 Stop Use and Ask a Doctor If ▾
Stop use and ask a doctor if redness, irritation, swelling, pain, or other symptoms occurs,or If condition worsens, or if symptoms persist for more than 7 days or clear up and occur again within a few days.
📄 Keep Out of Reach of Children ▾
Keep out of reach of children In case of accidental ingestion, seek medical help immediately.
📄 Package Label / Principal Display Panel ▾
Label.
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
Medicare Part D spend CMS · PART D · 2026 (Q1)
Medicare Part D (outpatient prescription) spending for Lidocaine (matched by generic name) — the program that covers self-administered drugs. 17 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Lidocaine. CMS lists 8 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$53.12M
Claims incl. refills
593.7K
Beneficiaries
367.9K
Spend / beneficiary
$144.39
Spend / claim
$89.46
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Adellina Numbing Cream (this brand).
Top reported reactions
Age at onset
Reporter sex
Male · 37%
Female · 63%
Unknown · 0%
Serious outcomes
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
About this NDC listing & data coverage
Over-the-counter (OTC) product
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Otc Monograph Drug". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Guangzhou Haishi Biological Technology Co., Ltd.. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Guangzhou Haishi Biological Technology Co., Ltd. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as an over-the-counter product, so it does not require a prescription. Follow the package directions, and ask your pharmacist if you are unsure whether it is right for you.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.